alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit
10.5
  AMENDMENT
TO
  EMPLOYMENT
AGREEMENT
  This
Amendment to Employment Agreement (this “Amendment”), dated November 15, 2009,
is made by and among American Oriental Bioengineering Inc., a Nevada corporation
(the “Company”), and Wilfred Chow, residing in New York, New York (the
“Executive”).  Any capitalized term not defined herein shall have the
meaning for such term specified in the Employment Agreement (as defined
below).
  WHEREAS, the Executive and the
Company entered into an Employment Agreement dated April 9, 2008, and effective
as of April 20, 2008 (the “Employment Agreement”);
 
 WHEREAS,  under the
Employment Agreement, the Executive was initially granted an option to
purchase a certain number of shares of common stock (the "Initial Option
Grant"), which number was based upon the Company's internal method for
valuing each share of common stock underlying the stock option at the time
of the grant (the "Per Share Value"), to reach a total annual compensation
value for accounting purposes (the "Total Value") ;
 
 WHEREAS, as the result of an
error in the calculation of the Per Share Value, the number of shares
issuable under the Initial Option Grant was incorrect and should have been lower
although the Total Value remains unchanged and the exercise price remains
unchanged from the date of the Initial Option Grant;
 
 WHEREAS, the Initial
Option Grant should be reduced and the Compensation Committee of the Board of
Directors has ratified, approved and confirmed in all respects, the
reduction in the Initial Option Grant;
  NOW THEREFORE,in
consideration of the foregoing and for other consideration, the receipt and
sufficiency of which is hereby acknowledged, the parties hereto, intending to be
legally bound, hereby agree as follows:
  1. Section 7
of the Employment Agreement is hereby amended by deleting “186,857” as the
number of shares of common stock that the Executive can purchase under the stock
options, and replacing it with “67,983.”
  2. Except as
specifically amended hereby, the Employment Agreement shall continue in full
force and effect unmodified and the parties hereby reaffirm the
same.
  3. This
Amendment shall be construed in accordance with and governed by the laws of the
State of New York, without giving effect to the conflict of laws principles
thereof.
  4. This
Amendment may be signed in any number of counterparts, each of which shall be an
original and all of which shall be deemed to be one and the same instrument,
with the same effect as if the signatures thereto and hereto were upon the same
instrument.  A facsimile signature shall be deemed to be an original
signature for purposes of this Amendment.
  [Remainder
of page intentionally left blank]
  
 
 IN WITNESS WHEREOF, the
parties hereto have duly executed this Amendment as of the day and year first
above written.
  AMERICAN ORIENTAL
      BIOENGINEERING, INC.By:  /s/ Tony
      LiuName: Tony
      LiuTitle:   Chairman
      and Chief Executive Officer
 
 EXECUTIVE:
  /s/ Wilfred
Chow
 Wilfred
Chow
Amendment to Employment Agreement with Aaron Finlay



 Exhibit 4.54 
 

 
 25 January, 2005 
 Mr Aaron Finlay 
 34 Webster Street 
 Nedlands WA 6009

 Dear Aaron 
 Following the completion of the Merger Agreement
with Control Delivery Systems Inc on 30 December 2005, I am pleased to confirm your continued appointment as Company Secretary for pSivida Limited. 
 pSivida Limited agrees that your current salary of A$275,000 per annum plus superannuation, car park facilities and any other benefits currently provided by pSivida and the entitlement to discretionary cash bonuses and option awards will
remain for a minimum period of two years from February 28, 2006 and will continue where there is a requirement for the Company to maintain an office or have an Australian resident Company Secretary. As you are aware, it is the intention of the
Company to move its head office functions to Boston and it is expected that in due course the Company will be a US incorporated group. 
 In the event that
the Company is no longer an Australian incorporated group prior to the expiration of two years, or your appointment as Company Secretary is no longer required, the Company agrees that you will be entitled to that balance of monies owed calculated
based on your total package with reference to the above minimum two year period in the form of a lump sum redundancy payment. In addition, your entitlement to the exercise of options granted under the ESOP will continue through to the expiration of
the options granted despite your having left the employment of pSivida Limited. 
 It is recognised that you will devote time to and receive remuneration and
incentives from AION Diagnostics and pSiNutria as Chief Financial Officer and Company Secretary in each case, in addition to the above as is currently the case. 
 We are very happy with all your efforts and valuable contributions made during this very important last two years, during which the company has seen rapid growth and the completion of the acquisition of the remaining shares in pSiMedica
that we did not already own, various fund raisings, the National Market NASDAQ listing and most recently the acquisition of Control Delivery Systems Inc. 
  

	
	Yours sincerely
	
	 /s/ Gavin Rezos

	Mr Gavin Rezos
	 Managing Director and Chief Executive Officer
 On behalf of the Board


  

					
	

	  	 pSivida Limited
  
 Level 12 BGC Centre, 28 The Esplanade, Perth WA 6000 Australia
  

1+61 8 9226 5099        1+61 8 9226 5499
  
 www.psivida@psivida.com             www.psivida.com
  
 ABN 78 009 232 026
I 

117TH CONGRESS 

1ST SESSION H. R. 3176 

To designate as wilderness certain National Forest System land in the State 

of Illinois, and for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

MAY 13, 2021 

Mr. CURTIS introduced the following bill; which was referred to the Committee 

on Natural Resources, and in addition to the Committee on Agriculture, 

for a period to be subsequently determined by the Speaker, in each case 

for consideration of such provisions as fall within the jurisdiction of the 

committee concerned 

A BILL 

To designate as wilderness certain National Forest System 

land in the State of Illinois, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Shawnee Wilderness 

5 Designation Act’’. 

6 SEC. 2. SHAWNEE WILDERNESS, ILLINOIS. 

7 (a) DESIGNATION.—In accordance with the Wilder8 ness Act (16 U.S.C. 1131 et seq.), there is designated as 

9 wilderness and as a component of the National Wilderness 


kjohnson on DSK79L0C42PROD with BILLS
2 

•HR 3176 IH

1 Preservation System, to be known as the ‘‘Shawnee Wil2 derness’’ (referred to in this Act as the ‘‘Wilderness’’), the 

3 approximately 289,000 acres of Forest Service land com4 prising the Shawnee National Forest in the State of Illi5 nois. 

6 (b) MAP; LEGAL DESCRIPTION.— 

7 (1) IN GENERAL.—As soon as practicable after 

8 the date of enactment of this Act, the Secretary of 

9 Agriculture (referred to in this Act as the ‘‘Sec10 retary’’) shall prepare a map and legal description of 

11 the Wilderness. 

12 (2) FORCE OF LAW.—The map and legal de13 scription prepared under paragraph (1) shall have 

14 the same force and effect as if included in this Act, 

15 except that the Secretary may correct clerical and 

16 typographical errors in the map and legal descrip17 tion. 

18 (3) AVAILABILITY.—The map and legal descrip19 tion prepared under paragraph (1) shall be on file 

20 and available for public inspection in the appropriate 

21 offices of the Forest Service. 

22 (c) ADMINISTRATION.—Subject to valid existing 

23 rights, the Wilderness shall be administered by the Sec24 retary in accordance with the Wilderness Act (16 U.S.C. 

25 1131 et seq.), except that any reference in that Act to 


kjohnson on DSK79L0C42PROD with BILLS
3 

•HR 3176 IH

1 the effective date shall be considered to be a reference to 

2 the date of enactment of this Act. 

Æ 


kjohnson on DSK79L0C42PROD with BILLS
Unassociated Document


    Exhibit
      10.2

    


    ALLONGE
      TO PROMISSORY NOTE

    


    THIS
      ALLONGE, made as of September 27, 2007 by Pineapple House of Brevard, Inc.,
      a
      Delaware corporation (the “Borrower”) and consented to by The Goldfield
      Corporation and Southeast Power Corporation (collectively the “Guarantors); is
      to be attached to and made a part of that certain Promissory Note dated November
      18, 2005, made by Borrower to Branch Banking and Trust Company (the “Lender”) in
      the principal amount of Fourteen Million and No/100 Dollars ($14,000,000.00)
      (the “Note”) which Note is as therein set forth.

    


    WHEREAS,
      there is due and owing under the above-described Note the principal sum of
      $6,292,199.15; and

    


    WHEREAS,
      Borrower and Lender desire to amend the Note.

    


    NOW,
      THEREFORE, the Promissory Note dated November 18, 2005 is amended as
      follows:

    


    REPAYMENT.
      Interest only on the outstanding principal balance of the Note shall be payable
      monthly, commencing October 18, 2007, and continuing on the same day of each
      and
      every consecutive month thereafter until November 18, 2008, on which date the
      entire principal sum outstanding under this Note plus accrued interest shall
      become due and payable (the “Maturity Date”).

    


    All
      other
      terms and conditions of said Promissory Note remain in full force and
      effect.

    


    IN
      WITNESS WHEREOF, the undersigned has executed this document the year first
      above
      written.

    


    BORROWER:

    Pineapple
      House of Brevard, Inc.

    


    By:
       /s/ Stephen
      R. Wherry  

           
      Stephen R. Wherry, Vice President

    


    GUARANTOR:                                                                    
      GUARANTOR:

    The
      Goldfield
      Corporation                                                 
Southeast
      Power Corporation 

    


    By:
       /s/ Stephen
      R. Wherry                                              
      By:
       /s/ Stephen
      R. Wherry  

    Stephen
      R. Wherry, Senior
      Vice                                      
        Stephen
      R. Wherry, Treasurer 

    President 

    LENDER:

    Branch
      Banking & Trust Co.

    


    By:
       /s/ Lori
      A. Baldwin   

                          
      Lori A. Baldwin, Vice President
M A N D A T E

TO THE 283RD DISTRICT COURT OF DALLAS COUNTY, GREETINGS:

Before our Court of Appeals for the Eighth District of Texas, on 2/11/15, the cause upon appeal

to revise or reverse your judgment between

ARTHUR JORDAN, Appellant,

No. 08-13-00301-CR and

THE STATE OF TEXAS, Appellee,

was determined; and therein our said Court made its order in these words:

The Court has considered this cause on the record and concludes the judgment should be

modified to reflect that Appellant entered a plea of “not true” to the enhancement paragraph, the

jury found the enhancement paragraph “true,” and that Mark Scott was the prosecutor. The

judgment of the court below, as so modified, is affirmed. This decision shall be certified below

for observance.

WHEREFORE, WE COMMAND YOU to observe the order of our said Court of

Appeals for the Eighth District of Texas, in this behalf, and in all things have it duly recognized,

obeyed and executed.

WITNESS, the Clerk of the Court of Appeals, with the Seal thereof affixed, at the City of

El Paso, this May 21, 2015

.

Denise Pacheco, Clerk

Trial Court No. F-1271156-T
#### UNITED STATES of America, Plaintiff-Appellee, v. Kevin Scott CONWAY, Defendant-Appellant.

No. 07-14284

Non-Argument Calendar.

United States Court of Appeals, Eleventh Circuit.

May 28, 2008.

Robert Augustus Harper, Jr., Tallahassee, FL, for Defendant-Appellant.

E. Bryan Wilson, Tallahassee, FL, Lennard B. Register, III, U.S. Attorney’s Office, Pensacola, FL, for Plaintiff-Appellee.

Before BARKETT, PRYOR and FAY, Circuit Judges.

PER CURIAM:

Robert Augustus Harper, appointed counsel for Kevin Scott Conway in this direct criminal appeal, has moved to withdraw from further representation of the appellant and filed a brief pursuant to *Anders v. California,*386 U.S. 738, 87 S.Ct. 1396, 18 L.Ed.2d 493 (1967). Counsel also filed a motion to allow Conway to file an appellate brief *pro se.*Our independent review of the entire record reveals that counsel’s assessment of the relative merit of the appeal is correct. Because independent examination of the entire record reveals no arguable issues of merit, counsel’s motion to withdraw is GRANTED, counsel’s motion to allow Conway to file an appellate brief *pro se*is DENIED as moot, and Conway’s conviction and sentence are AFFIRMED.
Exhibit
10.1


 


MariMed
Inc.


 


SECOND
AMENDMENT TO EMPLOYMENT AGREEMENT


Effective
Date: May 12, 2022


 


This
Second Amendment to the Employment Agreement (this “Agreement”) is between MARIMED INC., a Delaware corporation (the “Company”
or “MariMed”), and JON R. LEVINE, an individual (the “Executive”).


 


WHEREAS,
the Company and the Executive entered into an Employment Agreement effective as of dated July 1, 2021, as amended by the First Amendment
to Employment Agreement effective as of September 22, 2021, providing for the continued employment of the Executive as its Chief Financial
Officer (the “Original Agreement”); and


 


WHEREAS,
the Company and the Executive seeks to amend the Original Agreement in accordance with the terms of this Agreement.


 


NOW,
THEREFORE, in consideration of good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties
hereto agree as follows:


 


1. The
Original Agreement is hereby amended as follows:


 


(a)
Section 2(a) of the Original Agreement is hereby amended to change Executive’s title, duties and responsibilities and as amended
Section 2(a) shall read as follows:


 


“During
the Term, the Executive will serve as the Chief Administrative Officer of the Company. The Executive will have such duties and responsibilities
as are customary for the position of Chief Administrative Officer including oversight of the Company’s strategic growth plan and
day-to-day operations, and supervision and oversight of the Company’s finance, sales, marketing and human relations function, and
such other duties and responsibilities as are reasonably assigned to him by the Board of Directors of the Company (the “Board”).
The Executive shall report to and be supervised by the Board.”; and


 


(b)
All references to “Chief Financial Officer” are hereby amended and replaced with “Chief Administrative Officer.”


 


2. Except
as otherwise amended by this Agreement, all other provisions of the Agreement shall remain in full force and effect.


 


[SIGNATURE
PAGE FOLLOWS ON THE NEXT PAGE]


 




    	 



     


    

 


The
undersigned hereby execute this Agreement as of the Effective Date stated above.


 


	MARIMED INC.	 
	 	 	 
	By:	 	 
	 	Robert Fireman	 
	 	Chief Executive Officer	 
	 	 	 
	 	 	 
	 	Jon R. Levine	 


 




    	2
IIB 

117TH CONGRESS 

2D SESSION H. R. 3285 

IN THE SENATE OF THE UNITED STATES 

JUNE 22, 2022 

Received; read twice and referred to the Committee on the Judiciary 

AN ACT 

To amend gendered terms in Federal law relating to the 

President and the President’s spouse. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 


kjohnson on DSK79L0C42PROD with BILLS
2 

HR 3285 RFS

1 SECTION 1. SHORT TITLE. 

2 This Act may be cited as the ‘‘21st Century President 

3 Act’’. 

4 SEC. 2. MODERNIZATION OF TERMS RELATING TO THE 

5 PRESIDENT AND THE SPOUSE OF A PRESI6 DENT. 

7 Section 879(b)(1)(A) of title 18, United States Code, 

8 is amended by striking ‘‘the wife of a former President 

9 during his lifetime, the widow of a former President until 

10 her death or remarriage’’ and inserting ‘‘the spouse of a 

11 former President during a former President’s lifetime, the 

12 surviving spouse of a former President until the surviving 

13 spouse’s death or remarriage’’. 

Passed the House of Representatives June 21, 2022. 

Attest: CHERYL L. JOHNSON, 

Clerk. 

By KEVIN MCCUMBER, 

Deputy Clerk. 


kjohnson on DSK79L0C42PROD with BILLS
exv10w8xivy



 




Exhibit 10.8(iv)



Amendment to Employment Agreement



This Amendment to Employment Agreement is made and entered into effective as of September
25th, 2007 by and between TopSpin Medical (Israel) Ltd., of 2 Yodfat St., Lod 71291,
Israel (the “Company”) and Eyal Kolka, of 60 Hameri St., Givataim, Israel (the “Employee”).



WHEREAS, the Company and the Employee entered into a certain Employment Agreement dated as of April
25, 2001, as amended (the “Employment Agreement”); and



WHEREAS, in recognition of the Employee’s extraordinary efforts and significant contribution to the
growth and success of the Company. the Company and the Employee wish to amend the Employment
Agreement in the manner provided below.



NOW, THEREFORE, in consideration of the premises and the mutual promises herein made, and in
consideration of the representations, warranties, and covenants herein contained, the parties agree
as follows:





	1.	 	All terms not otherwise defined herein, shall have the meaning ascribed to them in
the Employment Agreement.
	 
	2.	 	Effective as of January 24th, 2007 (the “Effective Date”), Employee’s
Salary shall be increased to NIS 47,300 per month, to be linked to the increase of
the Consumer Price Index (“CPI”) from the CPI known on the Effective Date to the CPI
as known on the date of payment of the Salary.
	 
	3.	 	All other terms and conditions of the Employment Agreement shall remain unchanged
and in full force and effect.




IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above
written.




	 	 	 	 	 	 	 	 	 
	TopSpin Medical (Israel) Ltd.	 	 	 	Eyal Kolka	 	 
	 
	 	 	 	 	 	 	 	 
	By: 

Name:

	 	/s/ Neil Cohen /s/ Eyal Kolka
 

Neil Cohen & Eyal Kolka
	 	 
	 	/s/ Eyal Kolka
 

Signature
	 	 
	Title:

	 	Director & CFO and
Senior VP of Business Development
**EXHIBIT
      32.2**


**CERTIFICATION
      OF CO-PRINCIPAL EXECUTIVE OFFICER**


**PURSUANT
      TO 18 U.S.C. § 1350 ADOPTED PURSUANT TO**


**SECTION
      906 OF THE SARBANES-OXLEY ACT OF 2002**





Pursuant
      to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of
      section 1350, chapter 63 of title 18, United States Code), the undersigned
      officer of Pilgrim’s Pride Corporation (the “Company”), does hereby certify, to
      such officer’s knowledge, that:





The
      Annual Report on Form 10-K for the year ended September 30, 2006 (the “Form
      10-K”) of the Company fully complies with the requirements of Section 13(a) or
      15(d) of the Securities Exchange Act of 1934, and information contained in
      the
      Form 10-K fairly presents, in all material respects, the financial condition
      and
      results of operations of the Company.








Date:
                November 17, 2006
            /s/
                O.B. Goolsby, Jr.O.B.
                Goolsby, Jr.Co-Principal
                Executive Officer
EXHIBIT 32.1



CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



In connection with the Quarterly Report of SFBC International, Inc. (the Company) on Form 10-Q for the period ending March 31, 2005 as filed with the Securities and Exchange Commission on the date hereof (the Report), I Arnold Hantman, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:



1.

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and



2.

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.





| | /s/ARNOLDHANTMAN       
| | -----------------------
| | Chief Executive Officer



Date:  May 10, 2005



A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
CERTIFICATIONS

      I, Basil Parker, certify that:

1. I have reviewed this quarterly report on Form 10-QSB of Bioaccelerate Inc;

2. Based on my knowledge, this annual report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this annual
report;

3. Based on my knowledge, the financial statements, and other financial
information included in this annual report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this annual report;

4. The registrant's other certifying officers and I am responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

a) designed such disclosure controls and procedures to ensure that material
information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the
period in which this annual report is being prepared;

b) evaluated the effectiveness of the registrant's disclosure controls and
procedures as of a date within 90 days prior to the filing date of this annual
report (the "Evaluation Date"); and

c) Presented in this annual report our conclusions about the effectiveness of
the disclosure controls and procedures based on our evaluation as of the
Evaluation Date;

5. The registrant's other certifying officers and I have disclosed, based on our
most recent evaluation, to the registrant's auditors and the audit committee of
registrant's board of directors (or persons performing the equivalent
functions):

a) all significant deficiencies in the design or operation of internal controls
which could adversely affect the registrant's ability to record, process,
summarize and report financial data and have identified for the registrant's
auditors any material weaknesses in internal controls; and

b) Any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal controls; and

6. The registrant's other certifying officers and I have indicated in this
annual report whether or not there were significant changes in internal controls
or in other factors that could significantly affect internal controls subsequent
to the date of our most recent evaluation, including any corrective actions with
regard to significant deficiencies and material weaknesses.

Date: April 29, 2004


                        /s/ Basil Parker
                        -------------------------
                        Basil Parker
                        President & Director